Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest ...

These aren't for the faint of heart.

Blake Crouch wrote a popular science-fiction thriller novel that is just screaming for a Hollywood adaptation. So, what's the ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Here are Cathie Wood’s latest moves.

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and ...

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' ...

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from ...

Cathie Wood's ARK Invest purchased $41.2M in Tesla (TSLA) and $2.3M in Bullish while selling $25.3M in Roku shares. See full trade breakdown here.